Minimal invasive surgery following intra-arterial chemotherapy with DOC, CDDP and PEP combined with intravenous chemotherapy with 5-FU for tongue cancer

長谷川, 博; 鹿野, 真人; 佐藤, 栄需

doi:10.5981/jjhnc.37.29

Cited by 3 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, when reducing the treatment intensity via surgery, a question arises as to whether or not MIS can be applied. In that regard, we have shown that MIS is possible for OSCC patients of all ages if the therapeutic effect is CR or gPR after IADCPIVF 2,5) . In the current report, as a result of performing MIS on 21 OSCC patients aged ≥80 years, the 3-year OS rate was 100%, which was a very good prognosis.…”

Section: Discussionmentioning

confidence: 83%

“…Then, the surgical excision range is reduced as much as possible according to the therapeutic effect to preserve the functions of mastication, swallowing, and articulation. We previously proposed an intra-arterial chemotherapy regimen, using a method of intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin, combined with intravenous chemotherapy using 5-fluorouracil (IADCPIVF) [2][3][4][5] . This therapy may have a synergistic effect by using multiple anticancer drugs with different mechanisms, as well as an enhancing effect on continuous administration for a long time via a retrograde intraarterial catheter.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neoadjuvant intra-arterial chemotherapy to avoid reconstructive surgery for oral cancer patients aged ≥80 years

Kaneko

Kanno

Yamazaki

et al. 2022

Ann. Cancer Res. Therap.

Self Cite

View full text Add to dashboard Cite

Introduction: This study aimed to evaluate survival in patients aged ≥80 years with oral squamous cell carcinoma (OSCC) treated with intra-arterial chemotherapy using docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil (IADCPIVF). Methods: The present study was a retrospective analysis of 32 OSCC patients who were determined to require reconstructive surgery. We performed IADCPIVF as neoadjuvant chemotherapy and then minimally invasive surgeries (MIS) on patients with complete responses or good partial responses. Results:The study population included 16 patients with stage II OSCC, seven with stage III, and nine with stage IV. The primary tumor response rate was 100% (complete response rate, 37.5%; good partial response rate, 28.1%; and fair partial response rate, 34.4%). After IADCPIVF, 32 patients underwent surgery; MIS was performed on 21 patients. The 3-year overall survival rate was 76.5% (stage II, 77.9%; stage III, 85.7%; and stage IV, 55.6%). In the multivariate analysis of survival, clinical tumor response was a significant prognostic factor. The rate of grade 3 adverse events was 46.9%, and most of the events were due to mucositis in the area of the intra-arterial injection. Conclusion: IADCPIVF is highly safe and has an excellent antitumor effect by itself, so it may be a possible new treatment method with high curability, even for patients aged ≥80 years who want to avoid reconstructive surgery and preserve oral function.

show abstract

Section: Discussionmentioning

confidence: 83%